Invesco Ltd. Halozyme Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 1,911,660 shares of HALO stock, worth $90.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,911,660

Previous 2,223,938 14.04%

Holding current value

$90.9 Million

Previous $116 Million 6.08%

% of portfolio

0.02%

Previous 0.03%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$51.3 - $64.42 $16 Million - $20.1 Million	-312,278 Reduced 14.04%	1,911,660 $109 Million
Q2 2024 Aug 13, 2024	BUY	$37.81 - $52.4 $5.12 Million - $7.1 Million	135,528 Added 6.49%	2,223,938 $116 Million
Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $1.95 Million - $2.42 Million	57,776 Added 2.85%	2,088,410 $85 Million
Q4 2023 Feb 12, 2024	BUY	$33.32 - $42.1 $453,551 - $573,065	13,612 Added 0.67%	2,030,634 $75.1 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $16.7 Million - $20.2 Million	-459,123 Reduced 18.54%	2,017,022 $77.1 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $30.7 Million - $39.3 Million	-1,015,032 Reduced 29.07%	2,476,145 $89.3 Million
Q1 2023 May 12, 2023	SELL	$32.86 - $55.7 $82.6 Million - $140 Million	-2,514,274 Reduced 41.87%	3,491,177 $133 Million
Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $14.7 Million - $21.8 Million	366,954 Added 6.51%	6,005,451 $342 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $2.61 Million - $3.51 Million	67,802 Added 1.22%	5,638,497 $223 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $9.32 Million - $12.1 Million	249,572 Added 4.69%	5,570,695 $245 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $5.92 Million - $7.6 Million	-185,110 Reduced 3.36%	5,321,123 $212 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $5.63 Million - $7.21 Million	176,888 Added 3.32%	5,506,233 $221 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $12.4 Million - $15 Million	-322,277 Reduced 5.7%	5,329,345 $217 Million
Q2 2021 Aug 17, 2021	BUY	$38.84 - $51.31 $5.04 Million - $6.66 Million	129,888 Added 2.35%	5,651,622 $257 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $7.47 Million - $9.73 Million	189,126 Added 3.55%	5,521,734 $230 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $28.1 Million - $47.4 Million	1,086,911 Added 25.6%	5,332,608 $228 Million
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $14.5 Million - $16.7 Million	563,416 Added 15.3%	4,245,697 $112 Million
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $70,671 - $116,596	4,349 Added 0.12%	3,682,281 $98.7 Million
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $14.6 Million - $22.9 Million	-1,050,885 Reduced 22.22%	3,677,932 $66.2 Million
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $8.03 Million - $10.5 Million	-537,977 Reduced 10.21%	4,728,817 $83.8 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $1.83 Million - $2.13 Million	-120,615 Reduced 2.24%	5,266,794 $81.7 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $17.5 Million - $20.4 Million	1,183,551 Added 28.15%	5,387,409 $92.6 Million
Q1 2019 May 15, 2019	SELL	$13.94 - $17.58 $142,968 - $180,300	-10,256 Reduced 0.24%	4,203,858 $67.7 Million
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $56.2 Million - $78.6 Million	4,214,114 New	4,214,114 $61.7 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account